



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

NTP42

Cat. No.:	HY-129851
CAS No.:	2055599-51-2
Molecular Formula:	C ₂₅ H ₂₃ F ₂ N ₃ O ₅ S
Molecular Weight:	515.53
Target:	Prostaglandin Receptor
Pathway:	GPCR/G Protein
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 31.25 mg/mL (60.62 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.9398 mL	9.6988 mL	19.3975 mL
		5 mM		0.3880 mL	1.9398 mL	3.8795 mL
		10 mM		0.1940 mL	0.9699 mL	1.9398 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.03 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.03 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	NTP42 is a thromboxane A ₂ (TXA ₂) receptor antagonist with an IC ₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)-mediated [Ca ²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619 ^[1] . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) ^[2] .
IC ₅₀ & Target	TXA ₂
In Vivo	NTP42 (0.25 mg/kg BID) is potent in a monocrotaline (MCT)-induced PAH rat model (28-day drug treatment is initiated within 24 h post-MCT) in haemodynamic assessments. NTP42 reduces the MCT-induced PAH, including mean pulmonary arterial pressure (mPAP) and right systolic ventricular pressure (RSVP). Moreover, NTP42 is superior to Sildenafil and Selexipag in significantly reducing pulmonary vascular remodelling, inflammatory mast cell infiltration and fibrosis in MCT-treated

animals^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar-Kyoto rats ^[2]
Dosage:	0.25 mg/kg BID
Administration:	28-day drug treatment was initiated within 24 h post-MCT (60 mg/kg)
Result:	Reduced the MCT-induced PAH, including mPAP and RSVP.

REFERENCES

[1]. B. Therese KINSELLA, et al. Thromboxane receptor antagonists. WO2016203314A1.

[2]. Eamon Mulvaney, et al. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA